Method for laserophoresis of biologically active substances

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely physiotherapy, and may be used for laserophoresis of biologically active substances of higher molecular weight. What is used is a low-intensity laser emission (LILE) by alternating various wave lengths and power densities every second day. At wave length 632-638 nm, power density makes 10-40 mWt/cm2. At wave length 780-785 nm, power density makes 20-90 mWt/cm2. Length of the exposure on one area makes 0.5-1 minute. Length of one session does not exceed 15 minutes.

EFFECT: implementing the method provides higher volumes of the substance of higher molecular weight introduced by laserophoresis in treating various dermatological diseases and eliminating cosmetic defects ensure by more optimal distribution of the introduced substance in biotissues.

3 cl, 3 dwg

 

The invention relates to medicine, in particular to physiotherapy, as a way of combined physical therapy effects, which can be used for the treatment of dermatological diseases and eliminate cosmetic defects (e.g., wrinkles).

There is a method of introducing a drug into a living body, namely, that the drug pre-applied to the skin, effect of helium-neon laser (wavelength 632.8 nm) at a power density of radiation 1-10 mW/cm for 5-10 minutes [prototype - ed. St. SU 1012923, MKI A61N 5/00. / Ingeniou, Yea, Temnata etc. - No. 3354461; Claimed 31.07.81. Publ. 23.04.1983].

However, this method does not allow to enter high-molecular compounds such as hyaluronic acid, which is widely used in medicine, because it is not provided with optimal energy and temporal parameters of the effect.

Also known is a method of treatment of disease, including the effects of medication means of dushirovanie mucous photosensitizer followed by radiation helium-neon laser, at the same time as medications using 0.25%oxolinic ointment, which is applied successively on each inflammation directly in front of the laser, when et is m irradiation is performed with the duration of 2 min per point with power flux-density of 100-120 mW/cm 2(2-3 treatments), then decrease to 20-25 mW/cm2(1-2 treatments), and on the stage of the resolution process, the exposure is carried out at a power density of 100-120 mW/cm2(1-2 treatments) [patent RU 2162719, MKI A61N 5/067. Method of treatment of stomatitis. / Mouseremote; Wraptors.- No. 2000112372/14;

Declared 19.05.2000. Publ. 10.02.2001].

This method of laserforce more efficient, because it better takes into account the physiology of biological tissues, the processes of penetration of substances, however, can also be successfully applied only when the introduction of the drug through the mucosal tissue.

Achievable technical result is to increase the number entered by laserforce substances of high molecular weight.

The proposed method of laserforce biologically active substances (BAS) differs from analogues to the fact that exposure is carried out alternately in a day of low-intensity laser radiation with different wavelength and power density, namely, the wavelength 632-638 nm and a power density of 10-40 mW/cm2the wavelength 780-785 nm and a power density of 20 to 90 mW/cm2while the exposure time for a single zone is 0.5 to 1 minute, and the total exposure time per session not to exceed 15 minutes, at the rate of 7-10 sessions. As BAS can be used, for example, hyaluronic acid.

When is the change proposed methodology for the effects of low-intensity laser radiation of different wavelengths is caused by the difference of the penetration depth, that provides the most optimal distribution of injected substances of high molecular weight in the tissue.

The need for sequential movement of the laser source on the surface due to the fact that the main mechanism of laserforce is cerebrity transport transcytosis are activated, and this process occurs in less than 1 minute [Glebov R.N. Biochemistry of membranes: Endocytosis and exocytosis. - M.: Higher school, 1987. - 95 S.; Moskvin SV, Minenkov A.A. Mechanism of transfer of drugs through the skin by the method of laserforce // Clinical dermatology and venereology. - 2010, No. 5. - P.78-84]. Therefore, to ensure maximum process efficiency it is necessary to move the laser emitter to use as large an area of the treated surface.

It is known that limiting the size of molecules that can penetrate the mechanism transcytosis are activated, is 1 μm or about 1000 kDa for molecules glomerular conformation, and the transcytosis are activated is Kalnyshevsky process, i.e. the effectiveness of the substance depends on the concentration of calcium ions in the cytosol [Glebov R.N. Biochemistry of membranes:

Endocytosis and exocytosis. - M.: Higher school, 1987. - 95 S.]. It is also known that the effect of low-intensity laser radiation with optimal settings allows you to increase inside the cellular concentration of calcium ions [Moskvin C. C. System performance analysis of biological control systems, low-energy laser radiation: author. Diss.... doctrinal. Sciences. - Tula, 2008. - 38 S.]. Creating the inventive method, the maximum possible concentration of calcium ions in the penetration zone, we create the best conditions for the penetration of substances, including increasing the efficiency of penetration of molecules critically large.

Studies have been conducted proving the effectiveness of the proposed methodology. As the input method laserforce substances was selected hyaluronic acid because it has a large molecular weight. In addition, there is a choice of hyaluronic acid of different molecular weight. The object of the study was the group of women aged 20 to 25 years (control) and four groups of 15 people, in whom were women aged from 38 to 55 years. In each of the groups differed in the method of exposure and the molecular weight of hyaluronic acid:

Control group: only the evaluation of the efficiency of oxygen exchange depending on age without effect.

group 1: the intervention was carried out according to the claimed method, the molecular weight of hyaluronic acid 1000 kDa.

group 2: Impacts was conducted for the claimed method, the molecular weight of hyaluronic acid 250 kDa.

3 g is the PAP: Only laser radiation with a wavelength of 628-635 nm, the power density of 25 mW/cm2molecular weight hyaluronic acid 750 kDa.

group 4: Only laser radiation with a wavelength of 628-635 nm, power density of 25 mW/cm2molecular weight hyaluronic acid 250 kDa.

As an indirect indicator of the effectiveness of laserforce number of injected substances of high molecular weight was used, the relative changes of the parameters of the microcirculation of the skin, because these indicators are the most versatile way to characterize the dynamics of change in the physiology of the skin. For "normal" were selected parameters of microcirculation of the skin of young women.

The impact of the spent laser therapeutic apparatus LASIK®, two radiating heads with laser diodes: a new CLAUSE (wavelength 635-638 nm, 10 mW) and CLO-780-90 (wavelength 780-785 nm, 50 mW). The distance to the skin surface provided special cosmetic nozzle.

The measurements were carried out on the complex multifunctional diagnostic "LACC-M", which is intended for non-invasive diagnosis of vital tissues. The complex provides a definition of an indicator of blood microcirculation in relative perfusion units, the level of functional oxyhemoglobin saturation of blood in the microvasculature in the interest of volumetric cravinho the various tissues in percent. In the "Fluorescence" complex provides the definition of the coefficient of the fluorescent contrast in the spectral range of 0.4-0.8 μm. The measurements were carried out on the temporal region of the patient at approximately the same time in the first half of the day.

The results of the study of microcirculation in the main group (relative changes of parameters) is presented in figure 1.

In the presence of various pathological processes in the tissues, and as a result of natural processes occurring during the aging process, changes the relative content of fluorophores. One of the most interesting objects of study are the system components of energy metabolism - reduced pyridine nucleotide (NADH, NADPH) and oxidized flavoprotein (flavine adenine dinucleotide, FAD). Each fluorophore has a characteristic absorption spectra and emission. With age there is a change in spatial structure (morphology) of the tissue, which leads to a change in its optical and spectral characteristics [Laser Doppler flowmetry blood microcirculation. A guide for physicians. Ed. Kropotkina A.I., Sidorov V.V.): JSC "Publishing house "Medicine", 2005. - 125 S.; Optical biomedical diagnostics: textbook. manual for schools. / Lane. from English. Ed. by V.V. Tuchina: 2 ttom 2. - M.: Fizmatlit, 2007. - 368 S.].

Accomplice parameters were measured using a multi-functional diagnostic complex "LACC-M" with the combination of the method of laser Doppler flowmetry, optical tissue oximetry and laser fluorescent diagnostics. The probe was mounted on the temporal area. If this diagnosis of the oxygen transport in the microvasculature and consumption of cloth was estimated complex characteristic of the efficiency of oxygen exchange, which is equal to the product of the microcirculation index (mean perfusion) on the index of the specific consumption of oxygen and the fluorescent indicator of oxygen consumption of enzymes involved in the respiratory chain [Laser Doppler flowmetry blood microcirculation. A guide for physicians. Ed. Kropotkina A.I., Sidorov V.V.): JSC "Publishing house "Medicine", 2005. - 125 S.; Optical biomedical diagnostics: textbook. manual for schools. / Lane. from English. edited Via: 2 so That 2. - M.: Fizmatlit, 2007. - 368 C.]. The measurements were carried out at the same time in the first half of the day at a room temperature of 23°C in sitting position after a 30 minute rest.

It is shown that depending on the age of the efficiency of oxygen exchange decreased almost 2-fold (Figure 2). When exposed by well-known methods (group 3 and group 4) virtually no evidence of any effect of, the change only at the level of experimental error (Figure 3), even for the molecular weight of 250 kDa, this mode is already insufficient. In Sodeistvie low-intensity laser radiation on the stated procedure allows hyaluronic acid with a molecular mass of 250 kDa, so, though to a lesser extent, with a molecular mass of 750 kDa.

Brief description of drawings

Figure 1. Relative changes (in %) of various parameters of microcirculation in the skin after applying the techniques laserforce hyaluronic acid.

1 - microcirculation Index (M)

2 - Saturation of the blood (SO2),

3 - the Relative volume fraction of erythrocytes (Vr),

4 - Index of perfusion saturation of oxygen in the microcirculation (Sm),

5 - the index of the specific consumption of oxygen in tissue (U),

6 - Saturation of arterial blood (SpO2),

7 - heart rate

Figure 2. Changes in the efficiency of the oxygen metabolism of the skin cells of a person depending on age.

Figure 3. Changes in the efficiency of the oxygen metabolism of the skin in different study groups.

Thus, we see that there is a normalization of indicators of microcirculation, and Central hemodynamics. There is also a recovery efficiency of oxygen exchange of the skin it is only after exposure at the stated procedure. With all the positive changes achieved its maximum value to 10 th procedure that corresponds to a known biorhythms normalization of physiological processes in the skin.

1. How laserforce biologically active substances with large molecular weight, including the introduction biologists who Eski active substances (BAS) and the implementation effects of low-intensity laser radiation (NEELY), characterized in that the impact alternately perform through the day NEELY with different wavelength and power density, namely wavelength 632-638 nm and a power density of 10-40 mW/cm2the wavelength 780-785 nm and a power density of 20 to 90 mW/cm2while the exposure time for a single zone is 0.5-1 min, and one session does not exceed 15 minutes

2. How laserforce biologically active substances with large molecular weight according to claim 1, characterized in that as substance use hyaluronic acid.

3. How laserforce biologically active substances with large molecular weight according to claim 1, characterized in that the rate of laserforce includes 7-10 sessions.



 

Same patents:

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to gynaecology, and may be used for treating cystic fibrosis of the breast in females of reproductive age. That is ensured by prescribing the burdock root extract Toxidont-May in a dose of 1 teaspoon in 1 glass of warm water 3 times a day for 3 months.

EFFECT: method provides higher clinical effectiveness ensured by anti-oestrogen actions of the preparation caused by stimulating formation of antiproliferative 2OHE1 in hormone-dependent tissues and improving thereby the relation 2-OHE1/16αOHE1 in favour of the first with no side effects.

2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to gynaecology, and may be used for treating cystic fibrosis of the breast in females of reproductive age. That is ensured by prescribing the Burdock Seed preparation 3 capsules 3 times a day with meal for 6 weeks.

EFFECT: method provides higher clinical effectiveness in cystic fibrosis of the breast ensured by antiproliferative action of the preparation: accurate decrease in tumour necrosis factor alpha (TNF-α) responsible for stimulation of proliferative processes and increase in the content of interleukin-10 (IL10) showing antiproliferative action, and normalisation of a prolactin level with no side effects; and also provides extended range of products used for treating nonneoplastic diseases of the breast.

2 ex, 2 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to immunology and biotechnology. There are offered versions of a TNF-alpha polypeptide wherein a number of heavy-chain single domain antibodies is equal to two. What is described is coding nucleic acid. There are disclosed versions of the compositions, a polypeptide-based kit, as well as versions of using it. What is described is a method for producing the polypeptide with using nucleic acid.

EFFECT: use of the invention provides the substantial growth of cytotoxicity lC50 (of the order of 10-9) that can find further application in therapy of TNFα-mediated disorders.

52 cl, 18 dwg, 11 tbl, 9 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine and aims at enteral detoxification accompanying treating immune disorders. It involves prescribing a relaxant prebiotic and an enterosorbent. The relaxant prebiotic is introduced in a therapeutic dose 8-12 hours prior to the introduction of the enterosorbent. Once a day in the therapeutic course of 3-5 days. If the relaxant action of the prebiotic appeared to be ineffective, it is prescribed again in the half therapeutic dose. Lactulose is used as said prebiotic. The enterosorbent is activated carbon, Polysorb MP, Enterosgel, Lactofiltrum.

EFFECT: method provides higher clinical effectiveness in the diseases accompanied by immune dysfunctions that is ensured by enteral body detoxification.

1 ex, 3 cl

FIELD: chemistry.

SUBSTANCE: invention relates to a compound of general formula (I), salts and solvates thereof as ligands for G-protein conjugated receptors, , as well as a library consisting of elements which are compounds of formula (I). In general formula (I) , y equals 1 or 2; z equals 0; X denotes -CO-(Y)k-(R1)n, or SO2-(Y)k-(R1)n; k equals 0; each R1 is independently selected from hydrogen or alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, alkylamino, alkylaminoalkyl, alkylaminodialkyl, having an alkylaminotrialkyl charge or having an alkylcarboxylate charge from 1-20 carbon atoms; or each R1 is independently selected from fluorine, chlorine, bromine, iodine, hydroxy, oxyalkyl, amino, aminoalkyl, aminodialkyl, having the charge of aminotrialkyl or a carboxylate radical; n is an integer from 1 to m, where m is the maximum number of allowable substitutes; R1 contains a carbon atom next to the carbonyl group of carbonamide or the sulphonyl group of sulphanilamide, which is di-substituted or identical or different groups selected from: alkyl, haloalkyl, alkoxy, haloakoxy, alkenyl, alkynyl and aklylamino radical; and the carbon atom next to the carbonyl group of carbonamide or the sulphonyl group of sulphanilamide in R1 forms essentially tetrahedral valence-bond angles.

EFFECT: obtaining a compound, salt or solvates thereof for use as ligands for G-protein conjugated receptors.

4 cl, 4 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely oncology, and can be used for treating cervical cancer. That is ensured by radiation teletherapy and brachytherapy. Each brachytherapy session is preceded by bringing the Hydrogel Coletex-M Tissue 3-5 ml to the tumour before 12-18 hours. Before gel contact, the Coletex-M Tissue is introduced. Further,1-1,5 hours prior to the brachytherapy session, the textile tissue is removed, and Hydrogel Coletex-ADL Tissue 4-6 ml is brought to the tumour. Preliminary, the Hydrogel Coletex-ADL Tissue is added with lidocaine to achieve the gel concentration 4-6%.

EFFECT: method provides reduced total toxicity and drug load ensured by the required concentration of metronidazole maintained in the tumour before the radiation session, and also analgesia without using narcotic preparations, optimised time and geometry of centring introduction that allows intensifying the damage exposure on the tumour.

2 ex

FIELD: chemistry.

SUBSTANCE: invention relates to humanised anti-beta 7 antibodies; a composition containing said antibody; a method of inhibiting interaction of human integrin beta 7 subunits with a second integrin subunit using said antibody; as well as a version of use of the listed antibodies.

EFFECT: invention can be used to treat chronic inflammatory diseases such as asthma, Crohn's disease, ulcerative colitis, diabetes, complications during organ transplantation and diseases associated with allotransplantation.

47 cl, 22 dwg, 10 tbl, 3 ex

FIELD: chemistry.

SUBSTANCE: invention relates to an amine compound of formula (I), pharmaceutically acceptable addition salts, hydrates or solvates thereof, having immunodepressive effect , where R - H or P(=O)(OH)2; X - O or S; Y denotes -CH2CH2- or -CH=CH-; Z denotes C1-5-alkylene, C2-5-alkenylene or C2-5-alkynylene; R1 denotes CF3, R2 denotes C1-4-alkyl, substituted with OH or halogen; R3 and R4 independently denotes H < or C1-4-alkyl; A denotes optionally substituted C6-10-aryl, heteroaryl containing 5-10 ring atoms, where 1 or 2 atoms are selected from N, O and S, C3-7-cycloalkyl optionally condensed with optionally substituted benzene, or heterocycloalkyl containing 5-7 ring atoms, where 1 or 2 atoms are selected from N and O, where said substitutes are selected from C1-4-alkylthio, C1-4-alkylsulphanyl, C1-4-alkylsulphonyl, C2-5-alkylcarbonyl, halogen, cyano, nitro, C3-7-cycloalkyl, C6-10-aryl, C7-14-aralkyloxy, C6-10-aryloxy, optionally substituted with oxo or halogen, C2-3-alkyleneoxy, C3-4-alkylene or C1-2-alkylenedioxy, optionally substituted with halogen C1-4-alkyl or C1-4-alkoxy.

EFFECT: novel compound which is effective in reducing the level of lymphocytes in peripheral blood, suppresses tissue breakdown and exhibiting less side effects, such as bradycardia, is disclosed.

20 cl, 237 ex, 2 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely reflex therapy. A method involves biologically active zone exposure to a flame generated by burning of a wet cotton tincture. It is preceded by steaming the cotton in a herbal infusion, rolling it and used to massage. Then the cotton is smoothed down and placed on an exposure area. It is covered with bands impregnated with an alcoholate and set fire. A burning time is 7 to 30 seconds. The burning time and a number of setting fire is specified on the basis of individual tolerance.

EFFECT: method provides reduced length of body exposure required in various pathological conditions and ensured by improved skin penetration of biologically active substances contained in the herbal infusions.

2 tbl, 3 cl

Polycyclic compound // 2451685

FIELD: medicine, pharmaceutics.

SUBSTANCE: described is a new polycyclic compound with general formula (I-1) and (1-3) or a pharmaceutically acceptable salt thereof where X1- -CR1 =CR2 - where R1 and R2 independently stand for hydrogen or C1-6 alkyl while Het stands for a radical of the following formulae: that may be substituted 1-3 times additionally described is a pharmaceutical composition containing such compound and intended for prevention or treatment of diseases caused by β-amyloid.

EFFECT: production of a pharmaceutical composition prevention or treatment of diseases caused by β-amyloid.

7 cl, 392 ex, 12 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine and may be used in neurology, traumatology, physiotherapy, orthopaedics, in stepped therapy of protrusions, herniated disks, scoliosis, kyphosis, kyphoscoliosis, spondylolisthesis, osteochondrosis, myofascial syndrome, myositis, vertebrogenic (discogenic) torticollis, intercostal neuralgia, lumbago, lumbar ischialgia. The I stage consists in intravenous blood exposure to UV and red low-intensity laser emission, graduated uniform extension of all spinal segments in a traction apparatus with no fixation devices with considering patient's anthropometric data in complete muscular relaxation. The stage II consists of two alternating series of procedures. The series I implies paravertebral vacuum cup massage from both side upwards from a lumbar to cervical spine along massage lines of the back with a cup tightly pressed to skin. It is followed with vacuum gradient therapy with using a number of cups of different volumes and sections simultaneously along a venous outflow. Further, a leech therapy (LT) covering an umbilicus, a swing therapy (ST) in the SWING MACHINE training facility. The series II includes a one-day acupress therapy of the spinal muscular frame with using ebonite rollers along massage lines of the back, then - manual exposure on its musculo-ligamentous apparatus and joints in the form of various massage types, a yumeiho therapy, a postisometric relaxation, further the LT and the ST on the back area. The days free from the manual exposure and the LT on the back area; the ST is followed by physical exercises based on the system of traditional Cigun, Nishi, yoga techniques The stage III provides diagnosis and orthopaedic feet correction.

EFFECT: therapeutic effect is ensured by exposure on all the pathogenesis patterns of the spinal diseases: cell, immune, humoral, neuromuscular, mechanical, reflex, at the level of the integrated system, including principal drug-free recovery of the spinal health.

6 cl, 5 dwg, 5 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, oncology and radiology and consists in carrying out complex treatment by installation of endobronchial reverse valve into bleeding bronchus. At this background performed is external beam radiotherapy (EBRT) TFD 40 Gy, with radiomodifier: 5 fluorouracil - 250 mg, course dose - 4-5 g, or cysplatin - 10 mg, course dose - 120 mg, which are introduced daily, intravenously 30 minutes before the beginning of EBRT session. 14 days after completion of the first stage of EBRT fibrobronchoscopy (FBS) is performed with removal of bronchoblocker, and the second stage of EBRT TFD 30 Gy is performed to total dose for two stages EBRT TFD 70 Gy, with application of the same radiomodifiers in the same mode. 30 days after finishing EBRT FBS is made and is tumour remains in bronchus lumen or there is a suspicion of it, photodynamic preparation is introduced intravenously, and after 4 hours FBS and laser irradiation of tumour are carried out. Control examination of tracheobroncial tree is carried out after 30 days and after 26 months.

EFFECT: method ensures increase of life expectancy and improvement of its quality for patients with non-operable lung cancer complicated by hemorrhage.

1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely gynaecology, venereology and immunology, and is applicable for local immunocorrection of female infectious-inflammatory urogenital diseases caused by sexually-transmitted microorganisms. For this purpose, with underlying drug-induced therapy, the immunomodulatory therapy is used from first day of therapy by magnetic laser exposure on a uterus neck. The uterus neck is exposed by a gynecologic speculum which is removed after the procedure is completed. The magnetic laser exposure immediately covers a cervical canal. That is ensured by using a low-intensity laser with variable pulse generation. The magnetic field intensity makes 1.25 T. Pulse train frequency per minute is 30. A pulse interval is 100 msec. Length of the exposure is 5 minutes. The therapeutic course is 10 procedures.

EFFECT: method provides higher complex clinical effectiveness ensured by normalising local immunity factors, namely functional activity recovery of neutrophilic granulocytes of the cervical canal, higher concentration of pro-inflammatory cytokines, immunoglobulins A, M, G in the cervical canal.

3 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine and veterinary science. A method involves sequential intravenous introduction of a binary catalytic system (BCS): an oxidation catalyst - a metal complex and an oxidation substratum - ascorbic acid (AA). The oxidation catalyst is introduced in a maximally tolerable or lower doses, and AA - in doses related to molar ratio of the metal complex: AK=1:10. The method also involves local hyperthermia of the tumour with using near infra-red laser emission. The tumour temperature is maintained within the range of 43-45°C by adjusting laser power density. The emission is terminated after achieving the minimum power density maintaining the tumour temperature within the preset temperature range. The declared device comprises a near infra-red laser with emissive power switch-on, switch-off and adjustment systems, and optical system of laser beam formation, a tumour temperature control system with its output connected both with an input of a laser negative feedback system, a laser power density control system. The device comprises an additionally adjustable power density discriminator. An input of the laser power density discriminator is connected with an output of the laser power density control system. The output of the discriminator is connected to an input of the laser switch-off system.

EFFECT: invention provides higher clinical effectiveness.

5 cl, 1 dwg, 1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely dermatovenerology and is applicable for treating chronic infectious urethritis complicated by prostatitis. That is ensured by taking azithromycin 1.0 g (sumamed) once a day in 1st-7th-14th days combined with the complex therapy. The complex therapy involves rectal suppositories Dalargex, 1 suppository daily at bedtime No.10, prostate massage, rectal laser therapy and daily application of fluoroquinolone - gemifloxacin (factive) 1 tab. (320 mg) a day for 14 days.

EFFECT: method enables prolonged remission of the disease, higher life quality of the patients, recovers the reproductive function due to improved eradication of the opportunistic flora in the prostate secretion contents.

4 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely urology, is applicable for treating chronic cystitis. That is ensured by drug instillations into a bladder. In addition, the instillation is preceded by endovesical mucosal exposure to laser light of wave length 0.62 mcm. The instillation is followed by pubic exposure to laser light of wave length 0.86 mcm within a projection of the bladder. The duration of each procedure is 7 minutes; the therapeutic course is 10-12 procedures.

EFFECT: method provides higher clinical effectiveness ensured by pain pulse interruption and improved microcirculation and consequently prolonged drug staying in the bladder cavity as a result of the exposure to laser light before the instillation, and also by deeper drug penetration in bladder tissue as a result the epicutaneous exposure to laser light after the instillation.

1 dwg, 2 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely therapy, and is applicable for correction of cardiovascular disorders accompanying metabolic syndrome in the patients suffering osteoarthrosis. It involves the supravenous blood exposure at wave length 405 nm, light guide tip power 1.5 mWt, length of a procedure 5 minutes. It is followed by contact joints exposure at wave length 630 nm, pulse power 10 Wt, frequency 80 Hz. Knee joints are exposed for 2 minutes from 4 sides and with using a lability technique by beam scanning along an joint space for 2 minutes. Hip joints are exposed through a projection of inguinal ligament, greater trochanter, ischial tuberosity for 2 minutes and with using a lability technique by beam scanning along the joint space for 4 minutes. The therapeutic course includes 10 daily sessions.

EFFECT: method allows providing prolonged remission and lowered drug load ensured by eliminating inflammatory activity, lipid spectrum, coagulation hemostasis and carbohydrate metabolism disorders.

19 tbl

FIELD: medicine.

SUBSTANCE: invention refers to physiotherapeutic apparatuses and is applicable for vitality recovery after damaging exercises and mental overload, and for treating various diseases by laser reflex therapy. A presented apparatus comprises a handle body which integrates a laser diode coupled with a control unit with emission brought outside through an outlet on a pointed handle tip. A side surface of the handle comprises a general electrode also connected with the control unit. The control unit is connected to a power supply unit. In the presented apparatus, the power supply unit and the control unit are integrated in the handle, on an internal side surface of the outlet, there is an acupuncture point detector represented by a thin metal core of the diameter no more than 1 mm one end of which is bent so that it gets into a laser beam, and another one is connected to the control unit.

EFFECT: invention allows detecting the acupuncture points more precisely with using a laser beam.

1 dwg

FIELD: medicine.

SUBSTANCE: claimed invention relates to ophthalmology, namely to ophthalmic oncology and is intended for organ-preserving treatment of intraocular tumours. Transpupillary PDT is performed. After 3-20 days treansscleral PDT is carried out. After tumour devitalisation, total vitrectomy and endoresection of tumour is performed. Vitreous cavity is filled with substitute of vitreous body and laser coagulation of retina is carried out.

EFFECT: method ensures radical complete destruction of tumour with extension of indications to organ-preserving treatment with recovery of functional reserves of eye.

3 ex

FIELD: agriculture.

SUBSTANCE: invention relates to animal husbandry, in particular, to methods of prevention transport stress of pigs. The method consists in activation of physiological adaptation mechanisms by daily exposure of pulsed low-intensity infrared radiation on the skin surface in the zone of localisation of the biologically active centers (BAC) № 4, №23, №33, №37, №50, №59 with frequency of 600 Hz, with a capacity of 10 mW with exposure of 256 seconds to each center, ten days prior to transportation.

EFFECT: method enables to increase the level of BAC biopotential, reduce the loss of body weight during transportation and improve meat quality obtained after slaughter carcasses.

1 dwg, 2 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmacology, and represents a sterile injectable water-based composition in the form of gel for iintra-articular injection containing hyaluronic acid of molecular weight 0.1 to 10×106 Da in the amount of 1-100 mg/ml of water or one of its salts and optionally one or more other natural polysaccharides specified in a group consisting of chondroitin sulphate, keratan, keratan sulphate, heparin, heparan sulphate, cellulose and its derivatives, chitosan, xanthan, alginate and their salts, and also one or more polyalcohols in the amount of 0.0001-100 mg/ml of water, prepared by making a water-based formulation containing hyaluronic acid or one of its salts, optionally one or more other natural polysaccharides, and also one or more polyalcohols, sterilising it with wet steam; the prepared gel shows a coincidence frequency of the elasticity modulus G' and the viscosity modulus G" within the range 0 to 10 Hz preferentially 0.41 Hz ±0.41 Hz with G" exceeding G' if the coincidence frequency is found to be high.

EFFECT: invention provides higher degradation resistance of the gel, and also makes the gel visco-elastic.

11 cl, 8 ex, 11 dwg

Up!